Resultaträkning Veeva Systems Inc.
Aktier
VEEV
US9224751084
Avancerad medicinsk utrustning & teknologi
|
Marknaden stängd -
Andra börsplatser
|
5-dagars förändring | Förändring 1 jan. | ||
| 222,21 USD | +1,49 % |
|
−4,72 % | −0,46 % |
| 01-14 | Veeva Systems Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 01:30 PM | |
| 01-08 | Veeva Systems och BioMarin Pharmaceutical ingår långsiktigt partnerskap | MT |
| Skatteperiod: Januari | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1,47 md | 1,85 md | 2,16 md | 2,36 md | 2,75 md | |||||
Total Revenues | 1,47 md | 1,85 md | 2,16 md | 2,36 md | 2,75 md | |||||
Cost of Goods Sold, Total | 409 mn | 504 mn | 609 mn | 677 mn | 700 mn | |||||
Gross Profit | 1,06 md | 1,35 md | 1,55 md | 1,69 md | 2,05 md | |||||
Selling General & Admin Expenses, Total | 384 mn | 460 mn | 566 mn | 628 mn | 657 mn | |||||
R&D Expenses | 294 mn | 382 mn | 520 mn | 629 mn | 693 mn | |||||
Other Operating Expenses, Total | 678 mn | 842 mn | 1,09 md | 1,26 md | 1,35 md | |||||
Operating Income | 378 mn | 505 mn | 459 mn | 429 mn | 696 mn | |||||
Interest And Investment Income | 15,86 mn | 14,73 mn | 45,86 mn | 134 mn | 208 mn | |||||
Net Interest Expenses | 15,86 mn | 14,73 mn | 45,86 mn | 134 mn | 208 mn | |||||
Currency Exchange Gains (Loss) | 2,28 mn | −714 tn | 591 tn | 124 tn | −3,27 mn | |||||
Other Non Operating Income (Expenses) | 1,15 mn | - | 572 tn | - | 611 tn | |||||
EBT, Excl. Unusual Items | 397 mn | 520 mn | 506 mn | 563 mn | 902 mn | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | −3,08 mn | −7,2 mn | 2,98 mn | 24,82 mn | 22,62 mn | |||||
Legal Settlements | - | - | - | - | −5 mn | |||||
EBT, Incl. Unusual Items | 394 mn | 512 mn | 509 mn | 588 mn | 919 mn | |||||
Income Tax Expense | 14 mn | 84,92 mn | 21,39 mn | 62,32 mn | 205 mn | |||||
Earnings From Continuing Operations | 380 mn | 427 mn | 488 mn | 526 mn | 714 mn | |||||
Net Income to Company | 380 mn | 427 mn | 488 mn | 526 mn | 714 mn | |||||
Net Income - (IS) | 380 mn | 427 mn | 488 mn | 526 mn | 714 mn | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 380 mn | 427 mn | 488 mn | 526 mn | 714 mn | |||||
Net Income to Common Excl. Extra Items | 380 mn | 427 mn | 488 mn | 526 mn | 714 mn | |||||
Per aktie poster | ||||||||||
Net EPS - Basic | 2,52 | 2,79 | 3,14 | 3,27 | 4,41 | |||||
Basic EPS - Continuing Operations | 2,52 | 2,79 | 3,14 | 3,27 | 4,41 | |||||
Basic Weighted Average Shares Outstanding | 151 mn | 153 mn | 155 mn | 161 mn | 162 mn | |||||
Net EPS - Diluted | 2,36 | 2,63 | 3 | 3,22 | 4,32 | |||||
Diluted EPS - Continuing Operations | 2,36 | 2,63 | 3 | 3,22 | 4,32 | |||||
Diluted Weighted Average Shares Outstanding | 161 mn | 162 mn | 162 mn | 163 mn | 165 mn | |||||
Normalized Basic EPS | 1,65 | 2,12 | 2,04 | 2,19 | 3,48 | |||||
Normalized Diluted EPS | 1,54 | 2 | 1,95 | 2,15 | 3,41 | |||||
Kompletterande punkter | ||||||||||
EBITDA | 407 mn | 533 mn | 488 mn | 462 mn | 736 mn | |||||
EBITA | 398 mn | 524 mn | 478 mn | 448 mn | 715 mn | |||||
EBIT | 378 mn | 505 mn | 459 mn | 429 mn | 696 mn | |||||
EBITDAR | 420 mn | 547 mn | 504 mn | 478 mn | 750 mn | |||||
Total Revenues (As Reported) | 1,47 md | 1,85 md | 2,16 md | 2,36 md | 2,75 md | |||||
Effective Tax Rate - (Ratio) | 3,55 | 16,58 | 4,2 | 10,6 | 22,32 | |||||
Current Domestic Taxes | 11,87 mn | 66,01 mn | 140 mn | 156 mn | 307 mn | |||||
Current Foreign Taxes | 2,82 mn | 7,84 mn | 8,51 mn | 12,16 mn | 10,9 mn | |||||
Total Current Taxes | 14,7 mn | 73,84 mn | 149 mn | 168 mn | 318 mn | |||||
Deferred Domestic Taxes | −135 tn | 2,82 mn | −120 mn | −103 mn | −109 mn | |||||
Deferred Foreign Taxes | −566 tn | 8,26 mn | −7,82 mn | −1,98 mn | −3,67 mn | |||||
Total Deferred Taxes | −701 tn | 11,08 mn | −128 mn | −105 mn | −112 mn | |||||
Normalized Net Income | 248 mn | 325 mn | 316 mn | 352 mn | 564 mn | |||||
Kompletterande driftskostnadsposter | ||||||||||
Advertising Expense | - | - | - | - | - | |||||
Selling and Marketing Expenses | 235 mn | 288 mn | 349 mn | 381 mn | 397 mn | |||||
General and Administrative Expenses | 149 mn | 172 mn | 218 mn | 247 mn | 261 mn | |||||
Research And Development Expense From Footnotes | 294 mn | 382 mn | 520 mn | 629 mn | 693 mn | |||||
Net Rental Expense, Total | 13 mn | 14 mn | 16 mn | 16 mn | 14 mn | |||||
Stock-Based Comp., COGS (Total) | 32,54 mn | 41,09 mn | 56,6 mn | 59,72 mn | 57,97 mn | |||||
Stock-Based Comp., R&D Exp. (Total) | 63,54 mn | 83,84 mn | 142 mn | 173 mn | 186 mn | |||||
Stock-Based Comp., S&M Exp. (Total) | 40,57 mn | 56,83 mn | 87,51 mn | 90,86 mn | 90,18 mn | |||||
Stock-Based Comp., G&A Exp. (Total) | 48,35 mn | 52,88 mn | 66,23 mn | 70,27 mn | 103 mn | |||||
Total Stock-Based Compensation | 185 mn | 235 mn | 352 mn | 394 mn | 437 mn |
- Börsen
- Aktier
- VEEV Aktie
- Finanser Veeva Systems Inc.
- Resultaträkning
Välj din utgåva
All finansiell information anpassad till den nationella nivån
MarketScreener is also available in this country: United States.
Switch edition















